<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23758699</PMID><DateCompleted><Year>2014</Year><Month>02</Month><Day>13</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1423-0127</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>1</Issue><PubDate><Year>2013</Year><Month>Jun</Month><Day>13</Day></PubDate></JournalIssue><Title>Journal of biomedical science</Title><ISOAbbreviation>J Biomed Sci</ISOAbbreviation></Journal><ArticleTitle>Current progress in dengue vaccines.</ArticleTitle><Pagination><StartPage>37</StartPage><MedlinePgn>37</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/1423-0127-20-37</ELocationID><Abstract><AbstractText>Dengue is one of the most important emerging vector-borne viral diseases. There are four serotypes of dengue viruses (DENV), each of which is capable of causing self-limited dengue fever (DF) or even life-threatening dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). The major clinical manifestations of severe DENV disease are vascular leakage, thrombocytopenia, and hemorrhage, yet the detailed mechanisms are not fully resolved. Besides the direct effects of the virus, immunopathological aspects are also involved in the development of dengue symptoms. Although no licensed dengue vaccine is yet available, several vaccine candidates are under development, including live attenuated virus vaccines, live chimeric virus vaccines, inactivated virus vaccines, and live recombinant, DNA and subunit vaccines. The live attenuated virus vaccines and live chimeric virus vaccines are undergoing clinical evaluation. The other vaccine candidates have been evaluated in preclinical animal models or are being prepared for clinical trials. For the safety and efficacy of dengue vaccines, the immunopathogenic complications such as antibody-mediated enhancement and autoimmunity of dengue disease need to be considered.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wan</LastName><ForeName>Shu-Wen</ForeName><Initials>SW</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, National Cheng Kung University Medical College, Tainan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Chiou-Feng</ForeName><Initials>CF</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Shuying</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yu-Hung</ForeName><Initials>YH</Initials></Author><Author ValidYN="Y"><LastName>Yeh</LastName><ForeName>Trai-Ming</ForeName><Initials>TM</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Hsiao-Sheng</ForeName><Initials>HS</Initials></Author><Author ValidYN="Y"><LastName>Anderson</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Yee-Shin</ForeName><Initials>YS</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>06</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Biomed Sci</MedlineTA><NlmUniqueID>9421567</NlmUniqueID><ISSNLinking>1021-7770</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053059">Dengue Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014613">Vaccines, Attenuated</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003715" MajorTopicYN="N">Dengue</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053059" MajorTopicYN="N">Dengue Vaccines</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003716" MajorTopicYN="N">Dengue Virus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014613" MajorTopicYN="N">Vaccines, Attenuated</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>3</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>5</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>6</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>6</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>2</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23758699</ArticleId><ArticleId IdType="pmc">PMC3686670</ArticleId><ArticleId IdType="doi">10.1186/1423-0127-20-37</ArticleId><ArticleId IdType="pii">1423-0127-20-37</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Simmons CP, Farrar JJ, Nguyen vV, Wills B. Dengue. N Engl J Med. 2012;366:1423&#x2013;1432. doi: 10.1056/NEJMra1110265.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1110265</ArticleId><ArticleId IdType="pubmed">22494122</ArticleId></ArticleIdList></Reference><Reference><Citation>Guzman MG, Halstead SB, Artsob H, Buchy P, Farrar J, Gubler DJ, Hunsperger E, Kroeger A, Margolis HS, Martinez E. et al.Dengue: a continuing global threat. Nat Rev Microbiol. 2010;8:S7&#x2013;S16. doi: 10.1038/nrmicro2460.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrmicro2460</ArticleId><ArticleId IdType="pmc">PMC4333201</ArticleId><ArticleId IdType="pubmed">21079655</ArticleId></ArticleIdList></Reference><Reference><Citation>Henchal EA, Putnak JR. The dengue viruses. Clin Microbiol Rev. 1990;3:376&#x2013;396.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC358169</ArticleId><ArticleId IdType="pubmed">2224837</ArticleId></ArticleIdList></Reference><Reference><Citation>Clyde K, Kyle JL, Harris E. Recent advances in deciphering viral and host determinants of dengue virus replication and pathogenesis. J Virol. 2006;80:11418&#x2013;11431. doi: 10.1128/JVI.01257-06.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01257-06</ArticleId><ArticleId IdType="pmc">PMC1642597</ArticleId><ArticleId IdType="pubmed">16928749</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang CJ, Luh HW, Wang SH, Lin HJ, Lee SC, Hu ST. The heterogeneous nuclear ribonucleoprotein K (hnRNP K) interacts with dengue virus core protein. DNA Cell Biol. 2001;20:569&#x2013;577. doi: 10.1089/104454901317094981.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/104454901317094981</ArticleId><ArticleId IdType="pubmed">11747608</ArticleId></ArticleIdList></Reference><Reference><Citation>Netsawang J, Noisakran S, Puttikhunt C, Kasinrerk W, Wongwiwat W, Malasit P, Yenchitsomanus PT, Limjindaporn T. Nuclear localization of dengue virus capsid protein is required for DAXX interaction and apoptosis. Virus Res. 2009;147:275&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pubmed">19944121</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufmann B, Rossmann MG. Molecular mechanisms involved in the early steps of flavivirus cell entry. Microbes Infect. 2011;13:1&#x2013;9. doi: 10.1016/j.micinf.2010.09.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2010.09.005</ArticleId><ArticleId IdType="pmc">PMC3014442</ArticleId><ArticleId IdType="pubmed">20869460</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler G, Maxwell SE, Ruemmler C, Stollar V. Newly synthesized dengue-2 virus nonstructural protein NS1 is a soluble protein but becomes partially hydrophobic and membrane-associated after dimerization. Virology. 1989;171:302&#x2013;305. doi: 10.1016/0042-6822(89)90544-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0042-6822(89)90544-8</ArticleId><ArticleId IdType="pubmed">2525840</ArticleId></ArticleIdList></Reference><Reference><Citation>Welsch S, Miller S, Romero-Brey I, Merz A, Bleck CK, Walther P, Fuller SD, Antony C, Krijnse-Locker J, Bartenschlager R. Composition and three-dimensional architecture of the dengue virus replication and assembly sites. Cell Host Microbe. 2009;5:365&#x2013;375. doi: 10.1016/j.chom.2009.03.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2009.03.007</ArticleId><ArticleId IdType="pmc">PMC7103389</ArticleId><ArticleId IdType="pubmed">19380115</ArticleId></ArticleIdList></Reference><Reference><Citation>Flamand M, Megret F, Mathieu M, Lepault J, Rey FA, Deubel V. Dengue virus type 1 nonstructural glycoprotein NS1 is secreted from mammalian cells as a soluble hexamer in a glycosylation-dependent fashion. J Virol. 1999;73:6104&#x2013;6110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC112675</ArticleId><ArticleId IdType="pubmed">10364366</ArticleId></ArticleIdList></Reference><Reference><Citation>Avirutnan P, Punyadee N, Noisakran S, Komoltri C, Thiemmeca S, Auethavornanan K, Jairungsri A, Kanlaya R, Tangthawornchaikul N, Puttikhunt C. et al.Vascular leakage in severe dengue virus infections: a potential role for the nonstructural viral protein NS1 and complement. J Infect Dis. 2006;193:1078&#x2013;1088. doi: 10.1086/500949.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/500949</ArticleId><ArticleId IdType="pubmed">16544248</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobs MG, Robinson PJ, Bletchly C, Mackenzie JM, Young PR. Dengue virus nonstructural protein 1 is expressed in a glycosyl-phosphatidylinositol-linked form that is capable of signal transduction. FASEB J. 2000;14:1603&#x2013;1610. doi: 10.1096/fj.14.11.1603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.14.11.1603</ArticleId><ArticleId IdType="pubmed">10928995</ArticleId></ArticleIdList></Reference><Reference><Citation>Noisakran S, Dechtawewat T, Avirutnan P, Kinoshita T, Siripanyaphinyo U, Puttikhunt C, Kasinrerk W, Malasit P, Sittisombut N. Association of dengue virus NS1 protein with lipid rafts. J Gen Virol. 2008;89:2492&#x2013;2500. doi: 10.1099/vir.0.83620-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.83620-0</ArticleId><ArticleId IdType="pubmed">18796718</ArticleId></ArticleIdList></Reference><Reference><Citation>Somnuke P, Hauhart RE, Atkinson JP, Diamond MS, Avirutnan P. N-linked glycosylation of dengue virus NS1 protein modulates secretion, cell-surface expression, hexamer stability, and interactions with human complement. Virology. 2011;413:253&#x2013;264. doi: 10.1016/j.virol.2011.02.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2011.02.022</ArticleId><ArticleId IdType="pmc">PMC3089955</ArticleId><ArticleId IdType="pubmed">21429549</ArticleId></ArticleIdList></Reference><Reference><Citation>Falgout B, Chanock R, Lai CJ. Proper processing of dengue virus nonstructural glycoprotein NS1 requires the N-terminal hydrophobic signal sequence and the downstream nonstructural protein NS2a. J Virol. 1989;63:1852&#x2013;1860.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC250595</ArticleId><ArticleId IdType="pubmed">2522997</ArticleId></ArticleIdList></Reference><Reference><Citation>Munoz-Jordan JL, Sanchez-Burgos GG, Laurent-Rolle M, Garcia-Sastre A. Inhibition of interferon signaling by dengue virus. Proc Natl Acad Sci USA. 2003;100:14333&#x2013;14338. doi: 10.1073/pnas.2335168100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2335168100</ArticleId><ArticleId IdType="pmc">PMC283592</ArticleId><ArticleId IdType="pubmed">14612562</ArticleId></ArticleIdList></Reference><Reference><Citation>Niyomrattanakit P, Winoyanuwattikun P, Chanprapaph S, Angsuthanasombat C, Panyim S, Katzenmeier G. Identification of residues in the dengue virus type 2 NS2B cofactor that are critical for NS3 protease activation. J Virol. 2004;78:13708&#x2013;13716. doi: 10.1128/JVI.78.24.13708-13716.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.78.24.13708-13716.2004</ArticleId><ArticleId IdType="pmc">PMC533897</ArticleId><ArticleId IdType="pubmed">15564480</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Mohan PM, Padmanabhan R. Processing and localization of Dengue virus type 2 polyprotein precursor NS3-NS4A-NS4B-NS5. J Virol. 1992;66:7549&#x2013;7554.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC240467</ArticleId><ArticleId IdType="pubmed">1433530</ArticleId></ArticleIdList></Reference><Reference><Citation>Matusan AE, Pryor MJ, Davidson AD, Wright PJ. Mutagenesis of the Dengue virus type 2 NS3 protein within and outside helicase motifs: effects on enzyme activity and virus replication. J Virol. 2001;75:9633&#x2013;9643. doi: 10.1128/JVI.75.20.9633-9643.2001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.75.20.9633-9643.2001</ArticleId><ArticleId IdType="pmc">PMC114534</ArticleId><ArticleId IdType="pubmed">11559795</ArticleId></ArticleIdList></Reference><Reference><Citation>Benarroch D, Selisko B, Locatelli GA, Maga G, Romette JL, Canard B. The RNA helicase, nucleotide 5&#x2032;-triphosphatase, and RNA 5&#x2032;-triphosphatase activities of Dengue virus protein NS3 are Mg2+-dependent and require a functional Walker B motif in the helicase catalytic core. Virology. 2004;328:208&#x2013;218. doi: 10.1016/j.virol.2004.07.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2004.07.004</ArticleId><ArticleId IdType="pubmed">15464841</ArticleId></ArticleIdList></Reference><Reference><Citation>Munoz-Jordan JL, Laurent-Rolle M, Ashour J, Martinez-Sobrido L, Ashok M, Lipkin WI, Garcia-Sastre A. Inhibition of alpha/beta interferon signaling by the NS4B protein of flaviviruses. J Virol. 2005;79:8004&#x2013;8013. doi: 10.1128/JVI.79.13.8004-8013.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.79.13.8004-8013.2005</ArticleId><ArticleId IdType="pmc">PMC1143737</ArticleId><ArticleId IdType="pubmed">15956546</ArticleId></ArticleIdList></Reference><Reference><Citation>Umareddy I, Chao A, Sampath A, Gu F, Vasudevan SG. Dengue virus NS4B interacts with NS3 and dissociates it from single-stranded RNA. J Gen Virol. 2006;87:2605&#x2013;2614. doi: 10.1099/vir.0.81844-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.81844-0</ArticleId><ArticleId IdType="pubmed">16894199</ArticleId></ArticleIdList></Reference><Reference><Citation>Egloff MP, Decroly E, Malet H, Selisko B, Benarroch D, Ferron F, Canard B. Structural and functional analysis of methylation and 5&#x2032;-RNA sequence requirements of short capped RNAs by the methyltransferase domain of dengue virus NS5. J Mol Biol. 2007;372:723&#x2013;736. doi: 10.1016/j.jmb.2007.07.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2007.07.005</ArticleId><ArticleId IdType="pubmed">17686489</ArticleId></ArticleIdList></Reference><Reference><Citation>Ackermann M, Padmanabhan R. De novo synthesis of RNA by the dengue virus RNA-dependent RNA polymerase exhibits temperature dependence at the initiation but not elongation phase. J Biol Chem. 2001;276:39926&#x2013;39937. doi: 10.1074/jbc.M104248200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M104248200</ArticleId><ArticleId IdType="pubmed">11546770</ArticleId></ArticleIdList></Reference><Reference><Citation>Kittigul L, Pitakarnjanakul P, Sujirarat D, Siripanichgon K. The differences of clinical manifestations and laboratory findings in children and adults with dengue virus infection. J Clin Virol. 2007;39:76&#x2013;81. doi: 10.1016/j.jcv.2007.04.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2007.04.006</ArticleId><ArticleId IdType="pubmed">17507286</ArticleId></ArticleIdList></Reference><Reference><Citation>Gubler DJ. Dengue and dengue hemorrhagic fever. Clin Microbiol Rev. 1998;11:480&#x2013;496.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC88892</ArticleId><ArticleId IdType="pubmed">9665979</ArticleId></ArticleIdList></Reference><Reference><Citation>Srikiatkhachorn A, Green S. Markers of dengue disease severity. Curr Top Microbiol Immunol. 2009;338:67&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">19802579</ArticleId></ArticleIdList></Reference><Reference><Citation>Martina BE, Koraka P, Osterhaus AD. Dengue virus pathogenesis: an integrated view. Clin Microbiol Rev. 2009;22:564&#x2013;581. doi: 10.1128/CMR.00035-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CMR.00035-09</ArticleId><ArticleId IdType="pmc">PMC2772360</ArticleId><ArticleId IdType="pubmed">19822889</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandyopadhyay S, Lum LC, Kroeger A. Classifying dengue: a review of the difficulties in using the WHO case classification for dengue haemorrhagic fever. Trop Med Int Health. 2006;11:1238&#x2013;1255. doi: 10.1111/j.1365-3156.2006.01678.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-3156.2006.01678.x</ArticleId><ArticleId IdType="pubmed">16903887</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy BR, Whitehead SS. Immune response to dengue virus and prospects for a vaccine. Annu Rev Immunol. 2011;29:587&#x2013;619. doi: 10.1146/annurev-immunol-031210-101315.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-immunol-031210-101315</ArticleId><ArticleId IdType="pubmed">21219187</ArticleId></ArticleIdList></Reference><Reference><Citation>Barniol J, Gaczkowski R, Barbato EV, da Cunha RV, Salgado D, Martinez E, Segarra CS, Pleites Sandoval EB, Mishra A, Laksono IS. et al.Usefulness and applicability of the revised dengue case classification by disease: multi-centre study in 18 countries. BMC Infect Dis. 2011;11:106. doi: 10.1186/1471-2334-11-106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2334-11-106</ArticleId><ArticleId IdType="pmc">PMC3098176</ArticleId><ArticleId IdType="pubmed">21510901</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei HY, Yeh TM, Liu HS, Lin YS, Chen SH, Liu CC. Immunopathogenesis of dengue virus infection. J Biomed Sci. 2001;8:377&#x2013;388. doi: 10.1007/BF02255946.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF02255946</ArticleId><ArticleId IdType="pubmed">11549879</ArticleId></ArticleIdList></Reference><Reference><Citation>Green S, Rothman A. Immunopathological mechanisms in dengue and dengue hemorrhagic fever. Curr Opin Infect Dis. 2006;19:429&#x2013;436. doi: 10.1097/01.qco.0000244047.31135.fa.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.qco.0000244047.31135.fa</ArticleId><ArticleId IdType="pubmed">16940865</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitehorn J, Simmons CP. The pathogenesis of dengue. Vaccine. 2011;29:7221&#x2013;7228. doi: 10.1016/j.vaccine.2011.07.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.07.022</ArticleId><ArticleId IdType="pubmed">21781999</ArticleId></ArticleIdList></Reference><Reference><Citation>Yacoub S, Mongkolsapaya J, Screaton G. The pathogenesis of dengue. Curr Opin Infect Dis. 2013;26:284&#x2013;289. doi: 10.1097/QCO.0b013e32835fb938.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/QCO.0b013e32835fb938</ArticleId><ArticleId IdType="pubmed">23449140</ArticleId></ArticleIdList></Reference><Reference><Citation>Guzman A, Isturiz RE. Update on the global spread of dengue. Int J Antimicrob Agents. 2010;36(Suppl 1):S40&#x2013;S42.</Citation><ArticleIdList><ArticleId IdType="pubmed">20833000</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandey BD, Morita K, Hasebe F, Parquet MC, Igarashi A. Molecular evolution, distribution and genetic relationship among the dengue 2 viruses isolated from different clinical severity. Southeast Asian J Trop Med Public Health. 2000;31:266&#x2013;272.</Citation><ArticleIdList><ArticleId IdType="pubmed">11127324</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, Suntayakorn S, Endy TP, Raengsakulrach B, Rothman AL, Ennis FA, Nisalak A. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis. 2000;181:2&#x2013;9. doi: 10.1086/315215.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/315215</ArticleId><ArticleId IdType="pubmed">10608744</ArticleId></ArticleIdList></Reference><Reference><Citation>Cologna R, Rico-Hesse R. American genotype structures decrease dengue virus output from human monocytes and dendritic cells. J Virol. 2003;77:3929&#x2013;3938. doi: 10.1128/JVI.77.7.3929-3938.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.77.7.3929-3938.2003</ArticleId><ArticleId IdType="pmc">PMC150669</ArticleId><ArticleId IdType="pubmed">12634353</ArticleId></ArticleIdList></Reference><Reference><Citation>Leitmeyer KC, Vaughn DW, Watts DM, Salas R, Villalobos I, de C, Ramos C, Rico-Hesse R. Dengue virus structural differences that correlate with pathogenesis. J Virol. 1999;73:4738&#x2013;4747.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC112516</ArticleId><ArticleId IdType="pubmed">10233934</ArticleId></ArticleIdList></Reference><Reference><Citation>de Borba L, Strottmann DM, de Noronha L, Mason PW, Dos Santos CN. Synergistic interactions between the NS3(hel) and E proteins contribute to the virulence of dengue virus type 1. PLoS Negl Trop Dis. 2012;6:e1624. doi: 10.1371/journal.pntd.0001624.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0001624</ArticleId><ArticleId IdType="pmc">PMC3328427</ArticleId><ArticleId IdType="pubmed">22530074</ArticleId></ArticleIdList></Reference><Reference><Citation>Perng GC, Lei HY, Lin YS, Chokephaibulkit K. Dengue vaccines: challenge and confrontation. World J of Vaccines. 2011;1:109&#x2013;130. doi: 10.4236/wjv.2011.14012.</Citation><ArticleIdList><ArticleId IdType="doi">10.4236/wjv.2011.14012</ArticleId></ArticleIdList></Reference><Reference><Citation>Halstead SB. Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res. 2003;60:421&#x2013;467.</Citation><ArticleIdList><ArticleId IdType="pubmed">14689700</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang KJ, Yang YC, Lin YS, Huang JH, Liu HS, Yeh TM, Chen SH, Liu CC, Lei HY. The dual-specific binding of dengue virus and target cells for the antibody-dependent enhancement of dengue virus infection. J Immunol. 2006;176:2825&#x2013;2832.</Citation><ArticleIdList><ArticleId IdType="pubmed">16493039</ArticleId></ArticleIdList></Reference><Reference><Citation>Ubol S, Phuklia W, Kalayanarooj S, Modhiran N. Mechanisms of immune evasion induced by a complex of dengue virus and preexisting enhancing antibodies. J Infect Dis. 2010;201:923&#x2013;935. doi: 10.1086/651018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/651018</ArticleId><ArticleId IdType="pubmed">20158392</ArticleId></ArticleIdList></Reference><Reference><Citation>Ubol S, Halstead SB. How innate immune mechanisms contribute to antibody-enhanced viral infections. Clin Vaccine Immunol. 2010;17:1829&#x2013;1835. doi: 10.1128/CVI.00316-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CVI.00316-10</ArticleId><ArticleId IdType="pmc">PMC3008185</ArticleId><ArticleId IdType="pubmed">20876821</ArticleId></ArticleIdList></Reference><Reference><Citation>Halstead SB, Mahalingam S, Marovich MA, Ubol S, Mosser DM. Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes. Lancet Infect Dis. 2010;10:712&#x2013;722. doi: 10.1016/S1473-3099(10)70166-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(10)70166-3</ArticleId><ArticleId IdType="pmc">PMC3057165</ArticleId><ArticleId IdType="pubmed">20883967</ArticleId></ArticleIdList></Reference><Reference><Citation>Selin LK, Varga SM, Wong IC, Welsh RM. Protective heterologous antiviral immunity and enhanced immunopathogenesis mediated by memory T cell populations. J Exp Med. 1998;188:1705&#x2013;1715. doi: 10.1084/jem.188.9.1705.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.188.9.1705</ArticleId><ArticleId IdType="pmc">PMC2212518</ArticleId><ArticleId IdType="pubmed">9802982</ArticleId></ArticleIdList></Reference><Reference><Citation>Mongkolsapaya J, Dejnirattisai W, Xu XN, Vasanawathana S, Tangthawornchaikul N, Chairunsri A, Sawasdivorn S, Duangchinda T, Dong T, Rowland-Jones S, Yenchitsomanus PT, McMichael A, Malasit P, Screaton G. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat Med. 2003;9:921&#x2013;927. doi: 10.1038/nm887.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm887</ArticleId><ArticleId IdType="pubmed">12808447</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurane I, Innis BL, Nimmannitya S, Nisalak A, Meager A, Janus J, Ennis FA. Activation of T lymphocytes in dengue virus infections. High levels of soluble interleukin 2 receptor, soluble CD4, soluble CD8, interleukin 2, and interferon-gamma in sera of children with dengue. J Clin Invest. 1991;88:1473&#x2013;1480. doi: 10.1172/JCI115457.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI115457</ArticleId><ArticleId IdType="pmc">PMC295652</ArticleId><ArticleId IdType="pubmed">1939640</ArticleId></ArticleIdList></Reference><Reference><Citation>Mangada MM, Rothman AL. Altered cytokine responses of dengue-specific CD4+ T cells to heterologous serotypes. J Immunol. 2005;175:2676&#x2013;2683.</Citation><ArticleIdList><ArticleId IdType="pubmed">16081844</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatch S, Endy TP, Thomas S, Mathew A, Potts J, Pazoles P, Libraty DH, Gibbons R, Rothman AL. Intracellular cytokine production by dengue virus-specific T cells correlates with subclinical secondary infection. J Infect Dis. 2011;203:1282&#x2013;1291. doi: 10.1093/infdis/jir012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jir012</ArticleId><ArticleId IdType="pmc">PMC3069729</ArticleId><ArticleId IdType="pubmed">21335561</ArticleId></ArticleIdList></Reference><Reference><Citation>Malavige GN, Huang LC, Salimi M, Gomes L, Jayaratne SD, Ogg GS. Cellular and cytokine correlates of severe dengue infection. PLoS One. 2012;7:e50387. doi: 10.1371/journal.pone.0050387.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0050387</ArticleId><ArticleId IdType="pmc">PMC3510251</ArticleId><ArticleId IdType="pubmed">23209731</ArticleId></ArticleIdList></Reference><Reference><Citation>Gagnon SJ, Ennis FA, Rothman AL. Bystander target cell lysis and cytokine production by dengue virus-specific human CD4(+) cytotoxic T-lymphocyte clones. J Virol. 1999;73:3623&#x2013;3629.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC104137</ArticleId><ArticleId IdType="pubmed">10196254</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothman AL. Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nat Rev Immunol. 2011;11:532&#x2013;543. doi: 10.1038/nri3014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3014</ArticleId><ArticleId IdType="pubmed">21760609</ArticleId></ArticleIdList></Reference><Reference><Citation>Espada-Murao LA, Morita K. Dengue and soluble mediators of the innate immune system. Trop Med Health. 2011;39:53&#x2013;62. doi: 10.2149/tmh.2011-03.</Citation><ArticleIdList><ArticleId IdType="doi">10.2149/tmh.2011-03</ArticleId><ArticleId IdType="pmc">PMC3317598</ArticleId><ArticleId IdType="pubmed">22500137</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan SW, Lin CF, Yeh TM, Liu CC, Liu HS, Wang S, Ling P, Anderson R, Lei HY, Lin YS. Autoimmunity in dengue pathogenesis. J Formos Med Assoc. 2013;112:3&#x2013;11. doi: 10.1016/j.jfma.2012.11.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jfma.2012.11.006</ArticleId><ArticleId IdType="pubmed">23332423</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson R, Wang S, Osiowy C, Issekutz AC. Activation of endothelial cells via antibody-enhanced dengue virus infection of peripheral blood monocytes. J Virol. 1997;71:4226&#x2013;4232.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC191637</ArticleId><ArticleId IdType="pubmed">9151809</ArticleId></ArticleIdList></Reference><Reference><Citation>King CA, Anderson R, Marshall JS. Dengue virus selectively induces human mast cell chemokine production. J Virol. 2002;76:8408&#x2013;8419. doi: 10.1128/JVI.76.16.8408-8419.2002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.76.16.8408-8419.2002</ArticleId><ArticleId IdType="pmc">PMC155122</ArticleId><ArticleId IdType="pubmed">12134044</ArticleId></ArticleIdList></Reference><Reference><Citation>Juffrie M, van Der Meer GM, Hack CE, Haasnoot K, Sutaryo J, Veerman AJ, Thijs LG. Inflammatory mediators in dengue virus infection in children: interleukin-8 and its relationship to neutrophil degranulation. Infect Immun. 2000;68:702&#x2013;707. doi: 10.1128/IAI.68.2.702-707.2000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.68.2.702-707.2000</ArticleId><ArticleId IdType="pmc">PMC97195</ArticleId><ArticleId IdType="pubmed">10639436</ArticleId></ArticleIdList></Reference><Reference><Citation>Nascimento EJ, Silva AM, Cordeiro MT, Brito CA, Gil LH, Braga-Neto U, Marques ET. Alternative complement pathway deregulation is correlated with dengue severity. PLoS One. 2009;4:e6782. doi: 10.1371/journal.pone.0006782.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0006782</ArticleId><ArticleId IdType="pmc">PMC2728508</ArticleId><ArticleId IdType="pubmed">19707565</ArticleId></ArticleIdList></Reference><Reference><Citation>Avirutnan P, Malasit P, Seliger B, Bhakdi S, Husmann M. Dengue virus infection of human endothelial cells leads to chemokine production, complement activation, and apoptosis. J Immunol. 1998;161:6338&#x2013;6346.</Citation><ArticleIdList><ArticleId IdType="pubmed">9834124</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin CF, Lei HY, Liu CC, Liu HS, Yeh TM, Wang ST, Yang TI, Sheu FC, Kuo CF, Lin YS. Generation of IgM anti-platelet autoantibody in dengue patients. J Med Virol. 2001;63:143&#x2013;149. doi: 10.1002/1096-9071(20000201)63:2&lt;143::AID-JMV1009&gt;3.0.CO;2-L.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1096-9071(20000201)63:2&lt;143::AID-JMV1009&gt;3.0.CO;2-L</ArticleId><ArticleId IdType="pubmed">11170051</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito M, Oishi K, Inoue S, Dimaano EM, Alera MT, Robles AM, Estrella BD Jr, Kumatori A, Moji K, Alonzo MT. et al.Association of increased platelet-associated immunoglobulins with thrombocytopenia and the severity of disease in secondary dengue virus infections. Clin Exp Immunol. 2004;138:299&#x2013;303. doi: 10.1111/j.1365-2249.2004.02626.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2249.2004.02626.x</ArticleId><ArticleId IdType="pmc">PMC1809201</ArticleId><ArticleId IdType="pubmed">15498040</ArticleId></ArticleIdList></Reference><Reference><Citation>Oishi K, Inoue S, Cinco MT, Dimaano EM, Alera MT, Alfon JA, Abanes F, Cruz DJ, Matias RR, Matsuura H. et al.Correlation between increased platelet-associated IgG and thrombocytopenia in secondary dengue virus infections. J Med Virol. 2003;71:259&#x2013;264. doi: 10.1002/jmv.10478.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.10478</ArticleId><ArticleId IdType="pubmed">12938201</ArticleId></ArticleIdList></Reference><Reference><Citation>Falconar AK. The dengue virus nonstructural-1 protein (NS1) generates antibodies to common epitopes on human blood clotting, integrin/adhesin proteins and binds to human endothelial cells: potential implications in haemorrhagic fever pathogenesis. Arch Virol. 1997;142:897&#x2013;916. doi: 10.1007/s007050050127.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s007050050127</ArticleId><ArticleId IdType="pubmed">9191856</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin CF, Lei HY, Shiau AL, Liu CC, Liu HS, Yeh TM, Chen SH, Lin YS. Antibodies from dengue patient sera cross-react with endothelial cells and induce damage. J Med Virol. 2003;69:82&#x2013;90. doi: 10.1002/jmv.10261.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.10261</ArticleId><ArticleId IdType="pubmed">12436482</ArticleId></ArticleIdList></Reference><Reference><Citation>Falconar AK. Antibody responses are generated to immunodominant ELK/KLE-type motifs on the nonstructural-1 glycoprotein during live dengue virus infections in mice and humans: implications for diagnosis, pathogenesis, and vaccine design. Clin Vaccine Immunol. 2007;14:493&#x2013;504. doi: 10.1128/CVI.00371-06.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CVI.00371-06</ArticleId><ArticleId IdType="pmc">PMC1865631</ArticleId><ArticleId IdType="pubmed">17329445</ArticleId></ArticleIdList></Reference><Reference><Citation>Markoff LJ, Innis BL, Houghten R, Henchal LS. Development of cross-reactive antibodies to plasminogen during the immune response to dengue virus infection. J Infect Dis. 1991;164:294&#x2013;301. doi: 10.1093/infdis/164.2.294.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/164.2.294</ArticleId><ArticleId IdType="pubmed">1856477</ArticleId></ArticleIdList></Reference><Reference><Citation>Chungue E, Poli L, Roche C, Gestas P, Glaziou P, Markoff LJ. Correlation between detection of plasminogen cross-reactive antibodies and hemorrhage in dengue virus infection. J Infect Dis. 1994;170:1304&#x2013;1307. doi: 10.1093/infdis/170.5.1304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/170.5.1304</ArticleId><ArticleId IdType="pubmed">7963733</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YS, Yeh TM, Lin CF, Wan SW, Chuang YC, Hsu TK, Liu HS, Liu CC, Anderson R, Lei HY. Molecular mimicry between virus and host and its implications for dengue disease pathogenesis. Exp Biol Med (Maywood) 2011;236:515&#x2013;523. doi: 10.1258/ebm.2011.010339.</Citation><ArticleIdList><ArticleId IdType="doi">10.1258/ebm.2011.010339</ArticleId><ArticleId IdType="pubmed">21502191</ArticleId></ArticleIdList></Reference><Reference><Citation>Chuang YC, Lin YS, Liu CC, Liu HS, Liao SH, Shi MD, Lei HY, Yeh TM. Factors contributing to the disturbance of coagulation and fibrinolysis in dengue virus infection. J Formos Med Assoc. 2013;112:12&#x2013;17. doi: 10.1016/j.jfma.2012.10.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jfma.2012.10.013</ArticleId><ArticleId IdType="pubmed">23332424</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothman AL. Dengue: defining protective versus pathologic immunity. J Clin Invest. 2004;113:946&#x2013;951.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC379334</ArticleId><ArticleId IdType="pubmed">15057297</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Schaar HM, Wilschut JC, Smit JM. Role of antibodies in controlling dengue virus infection. Immunobiology. 2009;214:613&#x2013;629. doi: 10.1016/j.imbio.2008.11.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imbio.2008.11.008</ArticleId><ArticleId IdType="pubmed">19261353</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahala WM, Silva AM. The human antibody response to dengue virus infection. Viruses. 2011;3:2374&#x2013;2395. doi: 10.3390/v3122374.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v3122374</ArticleId><ArticleId IdType="pmc">PMC3280510</ArticleId><ArticleId IdType="pubmed">22355444</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufman BM, Summers PL, Dubois DR, Eckels KH. Monoclonal antibodies against dengue 2 virus E-glycoprotein protect mice against lethal dengue infection. Am J Trop Med Hyg. 1987;36:427&#x2013;434.</Citation><ArticleIdList><ArticleId IdType="pubmed">3826503</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlesinger JJ, Brandriss MW, Walsh EE. Protection of mice against dengue 2 virus encephalitis by immunization with the dengue 2 virus non-structural glycoprotein NS1. J Gen Virol. 1987;68(Pt 3):853&#x2013;857.</Citation><ArticleIdList><ArticleId IdType="pubmed">3819700</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufman BM, Summers PL, Dubois DR, Cohen WH, Gentry MK, Timchak RL, Burke DS, Eckels KH. Monoclonal antibodies for dengue virus prM glycoprotein protect mice against lethal dengue infection. Am J Trop Med Hyg. 1989;41:576&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">2817214</ArticleId></ArticleIdList></Reference><Reference><Citation>Duangchinda T, Dejnirattisai W, Vasanawathana S, Limpitikul W, Tangthawornchaikul N, Malasit P, Mongkolsapaya J, Screaton G. Immunodominant T-cell responses to dengue virus NS3 are associated with DHF. Proc Natl Acad Sci U S A. 2010;107:16922&#x2013;16927. doi: 10.1073/pnas.1010867107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1010867107</ArticleId><ArticleId IdType="pmc">PMC2947904</ArticleId><ArticleId IdType="pubmed">20837518</ArticleId></ArticleIdList></Reference><Reference><Citation>An J, Zhou DS, Zhang JL, Morida H, Wang JL, Yasui K. Dengue-specific CD8+ T cells have both protective and pathogenic roles in dengue virus infection. Immunol Lett. 2004;95:167&#x2013;174. doi: 10.1016/j.imlet.2004.07.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imlet.2004.07.006</ArticleId><ArticleId IdType="pubmed">15388257</ArticleId></ArticleIdList></Reference><Reference><Citation>Yauch LE, Zellweger RM, Kotturi MF, Qutubuddin A, Sidney J, Peters B, Prestwood TR, Sette A, Shresta S. A protective role for dengue virus-specific CD8+ T cells. J Immunol. 2009;182:4865&#x2013;4873. doi: 10.4049/jimmunol.0801974.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.0801974</ArticleId><ArticleId IdType="pmc">PMC2674070</ArticleId><ArticleId IdType="pubmed">19342665</ArticleId></ArticleIdList></Reference><Reference><Citation>Gil L, Lopez C, Lazo L, Valdes I, Marcos E, Alonso R, Gambe A, Martin J, Romero Y, Guzman MG. et al.Recombinant nucleocapsid-like particles from dengue-2 virus induce protective CD4+ and CD8+ cells against viral encephalitis in mice. Int Immunol. 2009;21:1175&#x2013;1183. doi: 10.1093/intimm/dxp082.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/intimm/dxp082</ArticleId><ArticleId IdType="pubmed">19692540</ArticleId></ArticleIdList></Reference><Reference><Citation>Gil L, Lopez C, Blanco A, Lazo L, Martin J, Valdes I, Romero Y, Figueroa Y, Guillen G, Hermida L. The cellular immune response plays an important role in protecting against dengue virus in the mouse encephalitis model. Viral Immunol. 2009;22:23&#x2013;30. doi: 10.1089/vim.2008.0063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/vim.2008.0063</ArticleId><ArticleId IdType="pubmed">19210225</ArticleId></ArticleIdList></Reference><Reference><Citation>Zompi S, Santich BH, Beatty PR, Harris E. Protection from secondary dengue virus infection in a mouse model reveals the role of serotype cross-reactive B and T cells. J Immunol. 2012;188:404&#x2013;416. doi: 10.4049/jimmunol.1102124.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1102124</ArticleId><ArticleId IdType="pmc">PMC3244532</ArticleId><ArticleId IdType="pubmed">22131327</ArticleId></ArticleIdList></Reference><Reference><Citation>Zompi S, Montoya M, Pohl MO, Balmaseda A, Harris E. Dominant cross-reactive B cell response during secondary acute dengue virus infection in humans. PLoS Negl Trop Dis. 2012;6:e1568. doi: 10.1371/journal.pntd.0001568.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0001568</ArticleId><ArticleId IdType="pmc">PMC3308930</ArticleId><ArticleId IdType="pubmed">22448292</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitehead SS, Blaney JE, Durbin AP, Murphy BR. Prospects for a dengue virus vaccine. Nat Rev Microbiol. 2007;5:518&#x2013;528. doi: 10.1038/nrmicro1690.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrmicro1690</ArticleId><ArticleId IdType="pubmed">17558424</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas SJ, Endy TP. Critical issues in dengue vaccine development. Curr Opin Infect Dis. 2011;24:442&#x2013;450. doi: 10.1097/QCO.0b013e32834a1b0b.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/QCO.0b013e32834a1b0b</ArticleId><ArticleId IdType="pubmed">21799408</ArticleId></ArticleIdList></Reference><Reference><Citation>Cassetti MC, Durbin A, Harris E, Rico-Hesse R, Roehrig J, Rothman A, Whitehead S, Natarajan R, Laughlin C. Report of an NIAID workshop on dengue animal models. Vaccine. 2010;28:4229&#x2013;4234. doi: 10.1016/j.vaccine.2010.04.045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2010.04.045</ArticleId><ArticleId IdType="pmc">PMC2919823</ArticleId><ArticleId IdType="pubmed">20434551</ArticleId></ArticleIdList></Reference><Reference><Citation>Yauch LE, Shresta S. Mouse models of dengue virus infection and disease. Antiviral Res. 2008;80:87&#x2013;93. doi: 10.1016/j.antiviral.2008.06.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2008.06.010</ArticleId><ArticleId IdType="pmc">PMC3048811</ArticleId><ArticleId IdType="pubmed">18619493</ArticleId></ArticleIdList></Reference><Reference><Citation>Zompi S, Harris E. Animal models of dengue virus infection. Viruses. 2012;4:62&#x2013;82. doi: 10.3390/v4010062.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v4010062</ArticleId><ArticleId IdType="pmc">PMC3280519</ArticleId><ArticleId IdType="pubmed">22355452</ArticleId></ArticleIdList></Reference><Reference><Citation>Blaney JE Jr, Sathe NS, Hanson CT, Firestone CY, Murphy BR, Whitehead SS. Vaccine candidates for dengue virus type 1 (DEN1) generated by replacement of the structural genes of rDEN4 and rDEN4Delta30 with those of DEN1. Virol J. 2007;4:23. doi: 10.1186/1743-422X-4-23.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-4-23</ArticleId><ArticleId IdType="pmc">PMC1819370</ArticleId><ArticleId IdType="pubmed">17328799</ArticleId></ArticleIdList></Reference><Reference><Citation>Brewoo JN, Kinney RM, Powell TD, Arguello JJ, Silengo SJ, Partidos CD, Huang CY, Stinchcomb DT, Osorio JE. Immunogenicity and efficacy of chimeric dengue vaccine (DENVax) formulations in interferon-deficient AG129 mice. Vaccine. 2012;30:1513&#x2013;1520. doi: 10.1016/j.vaccine.2011.11.072.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.11.072</ArticleId><ArticleId IdType="pmc">PMC4592107</ArticleId><ArticleId IdType="pubmed">22178727</ArticleId></ArticleIdList></Reference><Reference><Citation>Murrell S, Wu SC, Butler M. Review of dengue virus and the development of a vaccine. Biotechnol Adv. 2011;29:239&#x2013;247. doi: 10.1016/j.biotechadv.2010.11.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biotechadv.2010.11.008</ArticleId><ArticleId IdType="pubmed">21146601</ArticleId></ArticleIdList></Reference><Reference><Citation>Monath TP. Treatment of yellow fever. Antiviral Res. 2008;78:116&#x2013;124. doi: 10.1016/j.antiviral.2007.10.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2007.10.009</ArticleId><ArticleId IdType="pubmed">18061688</ArticleId></ArticleIdList></Reference><Reference><Citation>Eckels KH, Dubois DR, Putnak R, Vaughn DW, Innis BL, Henchal EA, Hoke CH Jr. Modification of dengue virus strains by passage in primary dog kidney cells: preparation of candidate vaccines and immunization of monkeys. Am J Trop Med Hyg. 2003;69:12&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">14740950</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhamarapravati N, Sutee Y. Live attenuated tetravalent dengue vaccine. Vaccine. 2000;18(Suppl 2):44&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">10821973</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun W, Edelman R, Kanesa-Thasan N, Eckels KH, Putnak JR, King AD, Houng HS, Tang D, Scherer JM, Hoke CH Jr, Innis BL. Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates. Am J Trop Med Hyg. 2003;69:24&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">14740952</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabchareon A, Lang J, Chanthavanich P, Yoksan S, Forrat R, Attanath P, Sirivichayakul C, Pengsaa K, Pojjaroen-Anant C, Chokejindachai W. et al.Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. Am J Trop Med Hyg. 2002;66:264&#x2013;272.</Citation><ArticleIdList><ArticleId IdType="pubmed">12139219</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabchareon A, Lang J, Chanthavanich P, Yoksan S, Forrat R, Attanath P, Sirivichayakul C, Pengsaa K, Pojjaroen-Anant C, Chambonneau L. et al.Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children. Pediatr Infect Dis J. 2004;23:99&#x2013;109. doi: 10.1097/01.inf.0000109289.55856.27.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.inf.0000109289.55856.27</ArticleId><ArticleId IdType="pubmed">14872173</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez V, Gimenez S, Tomlinson B, Chan PK, Thomas GN, Forrat R, Chambonneau L, Deauvieau F, Lang J, Guy B. Innate and adaptive cellular immunity in flavivirus-naive human recipients of a live-attenuated dengue serotype 3 vaccine produced in Vero cells (VDV3) Vaccine. 2006;24:4914&#x2013;4926. doi: 10.1016/j.vaccine.2006.03.066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2006.03.066</ArticleId><ArticleId IdType="pubmed">16632108</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas SJ, Eckels KH, Carletti I, De La Barrera R, Dessy F, Fernandez S, Putnak R, Toussaint JF, Sun W, Bauer K. et al.A phase II, randomized, safety and immunogenicity study of a re-derived, live-attenuated dengue virus vaccine in healthy adults. Am J Trop Med Hyg. 2013;88:73&#x2013;88. doi: 10.4269/ajtmh.2012.12-0361.</Citation><ArticleIdList><ArticleId IdType="doi">10.4269/ajtmh.2012.12-0361</ArticleId><ArticleId IdType="pmc">PMC3541749</ArticleId><ArticleId IdType="pubmed">23208878</ArticleId></ArticleIdList></Reference><Reference><Citation>Men R, Bray M, Clark D, Chanock RM, Lai CJ. Dengue type 4 virus mutants containing deletions in the 3&#x2032; noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys. J Virol. 1996;70:3930&#x2013;3937.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC190271</ArticleId><ArticleId IdType="pubmed">8648730</ArticleId></ArticleIdList></Reference><Reference><Citation>McArthur JH, Durbin AP, Marron JA, Wanionek KA, Thumar B, Pierro DJ, Schmidt AC, Blaney JE Jr, Murphy BR, Whitehead SS. Phase I clinical evaluation of rDEN4Delta30-200,201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity. Am J Trop Med Hyg. 2008;79:678&#x2013;684.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2590927</ArticleId><ArticleId IdType="pubmed">18981503</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitehead SS, Falgout B, Hanley KA, Blaney JE Jr, Markoff L Jr, Murphy BR. A live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3&#x2032; untranslated region is highly attenuated and immunogenic in monkeys. J Virol. 2003;77:1653&#x2013;1657. doi: 10.1128/JVI.77.2.1653-1657.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.77.2.1653-1657.2003</ArticleId><ArticleId IdType="pmc">PMC140839</ArticleId><ArticleId IdType="pubmed">12502885</ArticleId></ArticleIdList></Reference><Reference><Citation>Blaney JE Jr, Hanson CT, Hanley KA, Murphy BR, Whitehead SS. Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2. BMC Infect Dis. 2004;4:39. doi: 10.1186/1471-2334-4-39.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2334-4-39</ArticleId><ArticleId IdType="pmc">PMC524489</ArticleId><ArticleId IdType="pubmed">15461822</ArticleId></ArticleIdList></Reference><Reference><Citation>Blaney JE Jr, Hanson CT, Firestone CY, Hanley KA, Murphy BR, Whitehead SS. Genetically modified, live attenuated dengue virus type 3 vaccine candidates. Am J Trop Med Hyg. 2004;71:811&#x2013;821.</Citation><ArticleIdList><ArticleId IdType="pubmed">15642976</ArticleId></ArticleIdList></Reference><Reference><Citation>Durbin AP, Kirkpatrick BD, Pierce KK, Schmidt AC, Whitehead SS. Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine. Vaccine. 2011;29:7242&#x2013;7250. doi: 10.1016/j.vaccine.2011.07.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.07.023</ArticleId><ArticleId IdType="pmc">PMC3170437</ArticleId><ArticleId IdType="pubmed">21781997</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett AD, Monath TP, Barban V, Niedrig M, Teuwen DE. 17D yellow fever vaccines: new insights. A report of a workshop held during the World Congress on medicine and health in the tropics, Marseille, France, Monday 12 September 2005. Vaccine. 2007;25:2758&#x2013;2765. doi: 10.1016/j.vaccine.2006.12.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2006.12.015</ArticleId><ArticleId IdType="pubmed">17368349</ArticleId></ArticleIdList></Reference><Reference><Citation>Barban V, Girerd Y, Aguirre M, Gulia S, Petiard F, Riou P, Barrere B, Lang J. High stability of yellow fever 17D-204 vaccine: a 12-year restrospective analysis of large-scale production. Vaccine. 2007;25:2941&#x2013;2950. doi: 10.1016/j.vaccine.2006.06.082.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2006.06.082</ArticleId><ArticleId IdType="pubmed">16914238</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlaycheva LA, Chambers TJ. Neuroblastoma cell-adapted yellow fever 17D virus: characterization of a viral variant associated with persistent infection and decreased virus spread. J Virol. 2002;76:6172&#x2013;6184. doi: 10.1128/JVI.76.12.6172-6184.2002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.76.12.6172-6184.2002</ArticleId><ArticleId IdType="pmc">PMC136214</ArticleId><ArticleId IdType="pubmed">12021351</ArticleId></ArticleIdList></Reference><Reference><Citation>Guirakhoo F, Pugachev K, Zhang Z, Myers G, Levenbook I, Draper K, Lang J, Ocran S, Mitchell F, Parsons M. et al.Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J Virol. 2004;78:4761&#x2013;4775. doi: 10.1128/JVI.78.9.4761-4775.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.78.9.4761-4775.2004</ArticleId><ArticleId IdType="pmc">PMC387722</ArticleId><ArticleId IdType="pubmed">15078958</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrison D, Legg TJ, Billings CW, Forrat R, Yoksan S, Lang J. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. J Infect Dis. 2010;201:370&#x2013;377. doi: 10.1086/649916.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/649916</ArticleId><ArticleId IdType="pubmed">20059357</ArticleId></ArticleIdList></Reference><Reference><Citation>Poo J, Galan F, Forrat R, Zambrano B, Lang J, Dayan GH. Live-attenuated tetravalent fengue vaccine in dengue-naive children, adolescents, and adults in Mexico City: randomized controlled Phase 1 trial of safety and immunogenicity. Pediatr Infect Dis J. 2011;30:e9&#x2013;e11. doi: 10.1097/INF.0b013e3181fe05af.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0b013e3181fe05af</ArticleId><ArticleId IdType="pubmed">21042231</ArticleId></ArticleIdList></Reference><Reference><Citation>Capeding RZ, Luna IA, Bomasang E, Lupisan S, Lang J, Forrat R, Wartel A, Crevat D. Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines. Vaccine. 2011;29:3863&#x2013;3872. doi: 10.1016/j.vaccine.2011.03.057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.03.057</ArticleId><ArticleId IdType="pubmed">21477675</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S, Jiwariyavej V, Dulyachai W, Pengsaa K, Wartel TA. et al.Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet. 2012;380:1559&#x2013;1567. doi: 10.1016/S0140-6736(12)61428-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(12)61428-7</ArticleId><ArticleId IdType="pubmed">22975340</ArticleId></ArticleIdList></Reference><Reference><Citation>Halstead SB. Dengue vaccine development: a 75% solution? Lancet. 2012;380:1535&#x2013;1536. doi: 10.1016/S0140-6736(12)61510-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(12)61510-4</ArticleId><ArticleId IdType="pubmed">22975339</ArticleId></ArticleIdList></Reference><Reference><Citation>Putnak R, Barvir DA, Burrous JM, Dubois DR, D&#x2019;Andrea VM, Hoke CH, Sadoff JC, Eckels KH. Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys. J Infect Dis. 1996;174:1176&#x2013;1184. doi: 10.1093/infdis/174.6.1176.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/174.6.1176</ArticleId><ArticleId IdType="pubmed">8940206</ArticleId></ArticleIdList></Reference><Reference><Citation>Robert Putnak J, Coller BA, Voss G, Vaughn DW, Clements D, Peters I, Bignami G, Houng HS, Chen RC, Barvir DA. et al.An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model. Vaccine. 2005;23:4442&#x2013;4452. doi: 10.1016/j.vaccine.2005.03.042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2005.03.042</ArticleId><ArticleId IdType="pubmed">16005749</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaiswal S, Khanna N, Swaminathan S. Replication-defective adenoviral vaccine vector for the induction of immune responses to dengue virus type 2. J Virol. 2003;77:12907&#x2013;12913. doi: 10.1128/JVI.77.23.12907-12913.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.77.23.12907-12913.2003</ArticleId><ArticleId IdType="pmc">PMC262593</ArticleId><ArticleId IdType="pubmed">14610213</ArticleId></ArticleIdList></Reference><Reference><Citation>Men R, Wyatt L, Tokimatsu I, Arakaki S, Shameem G, Elkins R, Chanock R, Moss B, Lai CJ. Immunization of rhesus monkeys with a recombinant of modified vaccinia virus Ankara expressing a truncated envelope glycoprotein of dengue type 2 virus induced resistance to dengue type 2 virus challenge. Vaccine. 2000;18:3113&#x2013;3122. doi: 10.1016/S0264-410X(00)00121-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0264-410X(00)00121-3</ArticleId><ArticleId IdType="pubmed">10856791</ArticleId></ArticleIdList></Reference><Reference><Citation>Konishi E, Fujii A. Dengue type 2 virus subviral extracellular particles produced by a stably transfected mammalian cell line and their evaluation for a subunit vaccine. Vaccine. 2002;20:1058&#x2013;1067. doi: 10.1016/S0264-410X(01)00446-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0264-410X(01)00446-7</ArticleId><ArticleId IdType="pubmed">11803066</ArticleId></ArticleIdList></Reference><Reference><Citation>Guzman MG, Rodriguez R, Hermida L, Alvarez M, Lazo L, Mune M, Rosario D, Valdes K, Vazquez S, Martinez R. et al.Induction of neutralizing antibodies and partial protection from viral challenge in Macaca fascicularis immunized with recombinant dengue 4 virus envelope glycoprotein expressed in Pichia pastoris. Am J Trop Med Hyg. 2003;69:129&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">13677367</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly EP, Greene JJ, King AD, Innis BL. Purified dengue 2 virus envelope glycoprotein aggregates produced by baculovirus are immunogenic in mice. Vaccine. 2000;18:2549&#x2013;2559. doi: 10.1016/S0264-410X(00)00032-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0264-410X(00)00032-3</ArticleId><ArticleId IdType="pubmed">10775789</ArticleId></ArticleIdList></Reference><Reference><Citation>Clements DE, Coller BA, Lieberman MM, Ogata S, Wang G, Harada KE, Putnak JR, Ivy JM, McDonell M, Bignami GS. et al.Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys. Vaccine. 2010;28:2705&#x2013;2715. doi: 10.1016/j.vaccine.2010.01.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2010.01.022</ArticleId><ArticleId IdType="pmc">PMC2837772</ArticleId><ArticleId IdType="pubmed">20097152</ArticleId></ArticleIdList></Reference><Reference><Citation>Coller BA, Clements DE, Bett AJ, Sagar SL, Ter Meulen JH. The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease. Vaccine. 2011;29:7267&#x2013;7275. doi: 10.1016/j.vaccine.2011.07.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.07.021</ArticleId><ArticleId IdType="pmc">PMC3179979</ArticleId><ArticleId IdType="pubmed">21777637</ArticleId></ArticleIdList></Reference><Reference><Citation>Chin JF, Chu JJ, Ng ML. The envelope glycoprotein domain III of dengue virus serotypes 1 and 2 inhibit virus entry. Microbes Infect. 2007;9:1&#x2013;6. doi: 10.1016/j.micinf.2006.09.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2006.09.009</ArticleId><ArticleId IdType="pubmed">17196419</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermida L, Bernardo L, Martin J, Alvarez M, Prado I, Lopez C, Sierra Bde L, Martinez R, Rodriguez R, Zulueta A. et al.A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates. Vaccine. 2006;24:3165&#x2013;3171. doi: 10.1016/j.vaccine.2006.01.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2006.01.036</ArticleId><ArticleId IdType="pubmed">16490289</ArticleId></ArticleIdList></Reference><Reference><Citation>Leng CH, Liu SJ, Tsai JP, Li YS, Chen MY, Liu HH, Lien SP, Yueh A, Hsiao KN, Lai LW. et al.A novel dengue vaccine candidate that induces cross-neutralizing antibodies and memory immunity. Microbes Infect. 2009;11:288&#x2013;295. doi: 10.1016/j.micinf.2008.12.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2008.12.004</ArticleId><ArticleId IdType="pubmed">19114121</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen HW, Liu SJ, Li YS, Liu HH, Tsai JP, Chiang CY, Chen MY, Hwang CS, Huang CC, Hu HM, A consensus envelope protein domain III can induce neutralizing antibody responses against serotype 2 of dengue virus in non-human primates. Arch Virol. 2013. Epub ahead of print PubMed PMID: 23456422.</Citation><ArticleIdList><ArticleId IdType="pubmed">23456422</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen HW, Liu SJ, Liu HH, Kwok Y, Lin CL, Lin LH, Chen MY, Tsai JP, Chang LS, Chiu FF. et al.A novel technology for the production of a heterologous lipoprotein immunogen in high yield has implications for the field of vaccine design. Vaccine. 2009;27:1400&#x2013;1409. doi: 10.1016/j.vaccine.2008.12.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2008.12.043</ArticleId><ArticleId IdType="pubmed">19150476</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang CY, Liu SJ, Tsai JP, Li YS, Chen MY, Liu HH, Chong P, Leng CH, Chen HW. A novel single-dose dengue subunit vaccine induces memory immune responses. PLoS One. 2011;6:e23319. doi: 10.1371/journal.pone.0023319.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0023319</ArticleId><ArticleId IdType="pmc">PMC3149651</ArticleId><ArticleId IdType="pubmed">21826249</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahala WM, Kraus AA, Haymore LB, Accavitti-Loper MA, de Silva AM. Dengue virus neutralization by human immune sera: Role of envelope protein domain III-reactive antibody. Virology. 2009;392:103&#x2013;113. doi: 10.1016/j.virol.2009.06.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2009.06.037</ArticleId><ArticleId IdType="pmc">PMC2746956</ArticleId><ArticleId IdType="pubmed">19631955</ArticleId></ArticleIdList></Reference><Reference><Citation>Midgley CM, Bajwa-Joseph M, Vasanawathana S, Limpitikul W, Wills B, Flanagan A, Waiyaiya E, Tran HB, Cowper AE, Chotiyarnwong P. et al.An in-depth analysis of original antigenic sin in dengue virus infection. J Virol. 2011;85:410&#x2013;421. doi: 10.1128/JVI.01826-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01826-10</ArticleId><ArticleId IdType="pmc">PMC3014204</ArticleId><ArticleId IdType="pubmed">20980526</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams KL, Wahala WM, Orozco S, de Silva AM, Harris E. Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo. Virology. 2012;429:12&#x2013;20. doi: 10.1016/j.virol.2012.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2012.03.003</ArticleId><ArticleId IdType="pmc">PMC3683589</ArticleId><ArticleId IdType="pubmed">22537810</ArticleId></ArticleIdList></Reference><Reference><Citation>Henchal EA, Henchal LS, Schlesinger JJ. Synergistic interactions of anti-NS1 monoclonal antibodies protect passively immunized mice from lethal challenge with dengue 2 virus. J Gen Virol. 1988;69(Pt 8):2101&#x2013;2107.</Citation><ArticleIdList><ArticleId IdType="pubmed">3404125</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu SF, Liao CL, Lin YL, Yeh CT, Chen LK, Huang YF, Chou HY, Huang JL, Shaio MF, Sytwu HK. Evaluation of protective efficacy and immune mechanisms of using a non-structural protein NS1 in DNA vaccine against dengue 2 virus in mice. Vaccine. 2003;21:3919&#x2013;3929. doi: 10.1016/S0264-410X(03)00310-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0264-410X(03)00310-4</ArticleId><ArticleId IdType="pubmed">12922127</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa SM, Freire MS, Alves AM. DNA vaccine against the non-structural 1 protein (NS1) of dengue 2 virus. Vaccine. 2006;24:4562&#x2013;4564. doi: 10.1016/j.vaccine.2005.08.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2005.08.022</ArticleId><ArticleId IdType="pubmed">16140430</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa SM, Azevedo AS, Paes MV, Sarges FS, Freire MS, Alves AM. DNA vaccines against dengue virus based on the ns1 gene: the influence of different signal sequences on the protein expression and its correlation to the immune response elicited in mice. Virology. 2007;358:413&#x2013;423. doi: 10.1016/j.virol.2006.08.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2006.08.052</ArticleId><ArticleId IdType="pubmed">17020777</ArticleId></ArticleIdList></Reference><Reference><Citation>Falgout B, Bray M, Schlesinger JJ, Lai CJ. Immunization of mice with recombinant vaccinia virus expressing authentic dengue virus nonstructural protein NS1 protects against lethal dengue virus encephalitis. J Virol. 1990;64:4356&#x2013;4363.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC247903</ArticleId><ArticleId IdType="pubmed">2143542</ArticleId></ArticleIdList></Reference><Reference><Citation>Amorim JH, Diniz MO, Cariri FA, Rodrigues JF, Bizerra RS, Goncalves AJ, de Barcelos Alves AM, de Souza Ferreira LC. Protective immunity to DENV2 after immunization with a recombinant NS1 protein using a genetically detoxified heat-labile toxin as an adjuvant. Vaccine. 2012;30:837&#x2013;845. doi: 10.1016/j.vaccine.2011.12.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.12.034</ArticleId><ArticleId IdType="pubmed">22178517</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin CF, Wan SW, Cheng HJ, Lei HY, Lin YS. Autoimmune pathogenesis in dengue virus infection. Viral Immunol. 2006;19:127&#x2013;132. doi: 10.1089/vim.2006.19.127.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/vim.2006.19.127</ArticleId><ArticleId IdType="pubmed">16817755</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen MC, Lin CF, Lei HY, Lin SC, Liu HS, Yeh TM, Anderson R, Lin YS. Deletion of the C-terminal region of dengue virus nonstructural protein 1 (NS1) abolishes anti-NS1-mediated platelet dysfunction and bleeding tendency. J Immunol. 2009;183:1797&#x2013;1803. doi: 10.4049/jimmunol.0800672.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.0800672</ArticleId><ArticleId IdType="pubmed">19592650</ArticleId></ArticleIdList></Reference><Reference><Citation>Srivastava AK, Putnak JR, Warren RL, Hoke CH Jr. Mice immunized with a dengue type 2 virus E and NS1 fusion protein made in Escherichia coli are protected against lethal dengue virus infection. Vaccine. 1995;13:1251&#x2013;1258. doi: 10.1016/0264-410X(94)00059-V.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0264-410X(94)00059-V</ArticleId><ArticleId IdType="pubmed">8578812</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu H, Xu XF, Gao N, Fan DY, Wang J, An J. Preliminary evaluation of DNA vaccine candidates encoding dengue-2 prM/E and NS1: their immunity and protective efficacy in mice. Mol Immunol. 2013;54:109&#x2013;114. doi: 10.1016/j.molimm.2012.11.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2012.11.007</ArticleId><ArticleId IdType="pubmed">23270684</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>